Loading clinical trials...
Loading clinical trials...
An Open Label, Non-randomized Treatment Protocol of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Protease Inhibitor-experienced Patients With HIV-1 Infection (the Tipranavir Expanded Access Program)
This study was designed to provide early access to and evaluate the safety of TPV/r in PI-experienced patients with HIV-1 infection.
Age
All ages
Sex
All
Healthy Volunteers
No
1182.70.127 Health Services Center, Inc.
Anniston, Alabama, United States
1182.70.006 Spectrum Medical Group
Phoenix, Arizona, United States
1182.70.016 Health for Life Clinic
Little Rock, Arkansas, United States
1182.70.065
Anaheim, California, United States
1182.70.246
Baldwin Park, California, United States
1182.70.043
Fountain Valley, California, United States
1182.70.092
Fresno, California, United States
1182.70.057
Glendale, California, United States
1182.70.064
Harbor City, California, United States
1182.70.079
Long Beach, California, United States
Start Date
December 1, 2004
Primary Completion Date
August 1, 2005
Last Updated
November 30, 2016
Tipranavir
DRUG
Ritonavir
DRUG
Lead Sponsor
Boehringer Ingelheim
NCT06694805
NCT04142047
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07428330